Principia Announces Expansion of its BTK Franchise with PRN473 Topical - Seite 2

Anticipated key corporate milestones

Principia also announced anticipated key milestones for the company’s clinical development programs:

• Rilzabrutinib
  • 1H20 – Presentation of pemphigus Phase 2 Part B trial
  • 1H20 – Initiation of Phase 2 trial for IgG4-RD
  • 2H20 – Presentation of ITP Phase 2 trial
  • 2H21 – PEGASUS Phase 3 trial results (accelerated from 1H22)
• PRN473 Topical
  • 1H20 – Initiation of Phase 1 trial
  • 2020 – Phase 1 trial results
• SAR442168 / PRN2246
  • 1Q20 – Sanofi anticipates Phase 2b trial data in multiple sclerosis
  • 2020 – Principia Phase 3 co-funding decision

About Principia Biopharma
Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases. Principia’s proprietary Tailored Covalency platform differentiates the company’s investigational therapies from traditional small molecules and provides the potential to deliver the potency, selectivity and safety of injectable drugs while maintaining the convenience of a pill or cream. This highly reproducible approach enables the company to pursue multiple programs efficiently. Rilzabrutinib, a reversible covalent BTK inhibitor, is being evaluated in a Phase 3 clinical trial in patients with pemphigus -- an orphan autoimmune disease -- a Phase 2 clinical trial in patients with immune thrombocytopenia (ITP), and the company plans to initiate a Phase 2 clinical trial in patients with IgG4-related diseases. PRN2246/SAR442168, a covalent BTK inhibitor which crosses the blood-brain barrier, is being evaluated in a Phase 2 clinical trial in patients with multiple sclerosis and is partnered with Sanofi. PRN473 Topical, a reversible covalent BTK inhibitor plans to initiate a Phase 1 clinical trial for immune-mediated diseases. For more information, please visit www.principiabio.com.

Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Principia’s expectations regarding the Principia pipeline of product candidates, the design, progress, initiation, and timing of, and results from, its clinical trials and information regarding the timing, scope and success of clinical results and potential commercial opportunities. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Principia’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Principia’s business in general, see the risk factors set forth in Principia’s reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Principia specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Investor Contact
Christopher Chai, CFO
[e-mail]

Media Contact
Paul Laland, VP of Corporate Communications
[e-mail]

415.519.6610